FDA-Drug2014-04-30Class I
XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box
Dolphin Intertrade Corporation
Hazard
Marketed without an Approved NDA/ANDA: Products found to contain undeclared sibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Sold states
Nationwide
Affected count
8 bottles
Manufactured in
11314 Sw 135th Ct, N/A, Miami, FL, United States
Products
XIYOUJI QINGZHI CAPSULE, 300mg, 20 count box
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1250-2014Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief